PHARMACY

Teva launches generic Viagra

BY David Salazar

The first generic of Pfizer’s blockbuster erectile dysfunction drug has hit the market. Teva on Monday announced the launch of its Viagra (sildenafil citrate) generic, opening the Jerusalem-based company up to the roughly $1.4 billion market size that IQVIA data shows the drug had for the 12 months ended August 2017.

“The launch of Teva’s sildenafil tablets brings an affordable generic treatment option to the estimated 18 million men in the United States who are diagnosed with erectile dysfunction,” Teva executive vice president of North American commercial Brendan O’Grady said. “Our team has made it a priority to ensure that patients are able to access this medicine—through both traditional and more innovative channels.”

The company was allowed to launch its generic on Dec. 11, as part of a patent infringement settlement it reached with Pfizer in 2013. As part of the settlement, Teva will pay Pfizer a royalty for license to produce the generic.

Teva’s said that it would be offering a savings card that will allow eligible patients to pay as little as $0 out of pocket for the drug, with a maximum benefit of $100 per fill for up to six fills.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Flu season begins tracking across the South

BY Michael Johnsen

Nationwide, influenza-like activity is beginning to rise for the second week, barely eclipsing the national baseline the Centers for Disease Control and Prevention has established as an indicator that the current flu season is active.

For the week ended Dec. 2, 2.3% of patient visits reported through the U.S. Outpatient Influenza-like Illness Surveillance Network were due to influenza-like illness. Last year the flu season didn't officially start until closer to Christmas, or three weeks after the official start of the flu season this year. That season crested midway through February at a peak of 5.2% in ILI-related illness rates.

Currently three states are reporting high influenza activity, including Louisiana, Mississippi and South Carolina. Puerto Rico, Georgia, Hawaii and Texas have reported moderate influenza activity.
   

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Impax’s Coreg CR generic gets tentative FDA approval

BY David Salazar

The Food and Drug Administration has approved specialty pharmaceutical company Impax Labs’ generic of GlaxoSmithKline’s Coreg CR (carvedilol phosphate) extended-release capsules.

The Bridgewater, N.J. company, which is set to be acquired by Amneal in the coming year, said that its application would become eligible for final approval once marketing exclusivity expires in May 2018. The drug is indicated to treat mild-to-severe heart failure, left ventricular dysfunction following myocardial infarction and hypertension.

Impax’s generic will be available in 10-, 20-., 40- and 80-mg dosage strengths. The product had U.S. brand sales of roughly $206 million for the 12 months ended October 2017, according to data from IQVIA.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES